Author: digi

Best Practices for Timely Deviation Documentation in Pharma Stability Testing

In the pharmaceutical industry, timely and accurate deviation documentation is critical to maintaining GxP compliance, preserving data integrity, and demonstrating control over the stability program. Delays in logging or investigating deviations can trigger audit observations, misaligned data sets, and loss of product integrity. This article outlines proven best practices to ensure that deviations during stability…

Deviation and OOS Handling in Stability Testing, Pharmaceutical Quality and Practices

When to Extend Stability Testing After an OOS Result

Out-of-Specification (OOS) results during stability studies raise critical questions for pharmaceutical companies: Was the result valid? Should the batch be rejected? Or should the study be extended to gather additional data? Making the right decision is essential not just for scientific rigor but also for regulatory compliance. This tutorial walks you through when and how…

Out-of-Specification (OOS) Stability Studies, Regulatory Guidelines

SOP for Conducting Stability Studies for Topical Products in Compliance with US FDA and EMA Guidelines

SOP for Conducting Stability Studies for Topical Products in Compliance with US FDA and EMA Guidelines Procedure for Stability Testing of Topical Products According to US FDA and EMA Guidelines 1) Purpose The purpose of this SOP is to establish a standardized procedure for conducting stability studies on topical drug products in compliance with the…

Stability Studies SOP

ICH Q1E Data Use in Re-Test Period Justification

In pharmaceutical manufacturing, the re-test period is a critical parameter for active pharmaceutical ingredients (APIs) and certain drug products. Regulatory authorities expect this period to be scientifically justified using robust stability data. This article walks you through how to use ICH Q1E guidelines to justify re-test periods, ensuring your submission aligns with global expectations. 💡…

ICH Q1E and Stability Data Evaluation, Protocols and Reports

Creating a Shelf Life Justification Report for Regulatory Submission

When submitting a dossier for a new drug application or variation filing, one of the most critical elements is the shelf life justification report. This document provides statistical, scientific, and regulatory evidence that supports the claimed expiry of a pharmaceutical product. Based on ICH Q1E principles, the report ensures that your product’s shelf life is…

Shelf Life and Expiry, Shelf Life Prediction Models and Statistical Approaches

Handling OOS During Stability Storage Excursions

Out-of-Specification (OOS) results occurring during stability studies are always a concern — but when combined with a storage excursion event, they demand urgent and disciplined investigation. This article provides pharma professionals a step-by-step guide on handling OOS incidents that occur during or after stability chamber excursions, aligning with ICH Q1A(R2) and regulatory expectations. 📊 Understanding…

Out-of-Specification (OOS) Stability Studies, Regulatory Guidelines

SOP Template Structure for Stability Chamber Calibration

Writing a Standard Operating Procedure (SOP) for stability chamber calibration requires more than just listing steps. It must adhere to pharmaceutical documentation norms, regulatory expectations, and company-specific quality systems. This tutorial guides you through the essential elements of an SOP template for calibration of stability chambers, ensuring both clarity and compliance with global standards like…

Equipment and Calibration, Stability Chamber Calibration and SOPs

Checklist for OOS Handling Procedures in Stability Testing

Handling Out-of-Specification (OOS) results in pharmaceutical stability testing requires a disciplined and compliant approach. Regulatory bodies like the USFDA expect companies to follow well-documented and scientifically justified procedures to investigate and resolve OOS results without compromising data integrity. This checklist outlines a step-by-step framework to guide your team through proper OOS handling. ✅ Phase I:…

Deviation and OOS Handling in Stability Testing, Pharmaceutical Quality and Practices

Cross-Functional Review of Q1E Evaluation Output

In the pharmaceutical industry, ICH Q1E plays a pivotal role in assigning shelf life and ensuring the statistical robustness of stability data. However, evaluating the data is only one half of the compliance equation—the other half is performing a thorough, cross-functional review of the output. This tutorial provides step-by-step guidance on how to set up…

ICH Q1E and Stability Data Evaluation, Protocols and Reports

Case Study: OOS Investigation Breakdown and Regulatory Resolution

Out-of-Specification (OOS) results can trigger major compliance concerns in pharmaceutical manufacturing — especially when they occur during long-term stability studies. This case-based article walks through a real-world OOS incident, its detailed investigation process, root cause determination, and regulatory resolution steps. It offers a practical learning opportunity for QA professionals, analysts, and regulatory affairs teams. 🔍…

Out-of-Specification (OOS) Stability Studies, Regulatory Guidelines